Pharmacogenomics of a traditional Japanese herbal medicine (Kampo) for cancer therapy

Cancer Genomics and Proteomics

Volumn 4, Issue 2, 2007, Pages 81-91

  Efferth, Thomas ^a   Miyachi, Hayato ^b   Bartsch, Helmut ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b TOKAI UNIVERSITY   (Japan)

Author keywords

Cluster analysis; Individualized cancer treatment; Kampo; Pharmacogenomics; Review; Shikonin

Indexed keywords

ACETALDEHYDE; ALKYLATING AGENT; ASALEX; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); FTORDOPAN; HERBACEOUS AGENT; KAMPO; MESSENGER RNA; NATURAL PRODUCT; RIFAMYCIN; SHIKONIN; SULFORHODAMINE B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; GENE EXPRESSION PROFILING; HUMAN; IC 50; MEDICINAL PLANT; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

LITHOSPERMUM ERYTHRORHIZON;

EID: 34247388552     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Rauchensteiner F: Kampo - modern traditional medicine in Japan (Article in German). Deutsche Apotheker Zeitung 145: 37-45, 2005.
2. Dharmananda S: Kampo medicine. The practice of Chinese herbal medicine in Japan. http://www.itmonline.org/arts/kampo.htm (search date: Nov-04-2006).
3. Numi H, Patumraj S and Han JY: Asian traditional medicine (ATM): recent progress based on scientific evidence. Clin Hemorheol Microcirc 34: 85-88, 2006.
4. Okamoto H: Reconsideration of Japanese traditional herbal medicine: new field of research and clinical medicine. Mini Rev Med Chem 6: 543-547, 2006.
5. Yu F, Takahashi T, Moriya J, Kawaura K, Yamakawa J, Kusaka K, Itoh T, Morimoto S, Yamaguchi N and Kanda T: Traditional Chinese medicine and Kampo: a review from the distant past for the future. J Int Med Res 34: 231-239, 2006.
6. World Health Organization (WHO), WHO Monographs on Selected Medicinal Plants. Vol. 1. World Health Organization, Geneva, Switzerland, 1999.
7. Volm M, Koomägi R and Efferth T: Prediction of drug sensitivity and resistance of cancer by protein expression profiling. Cancer Genomics Proteomics 1: 157-166, 2004.
8. Efferth T and Volm M: Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 107: 155-176, 2005.
9. Efferth T, Koomägi R, Mattern J and Volm M: Protein expression profiles of non-small cell lung cancer of smokers. Cancer Genomics Proteomics 1: 249-254, 2004.
10. Efferth T and Volm M: Protein expression profiles indicative for drug resistance of kidney carcinoma. Cancer Genomics Proteomics 1: 17-22, 2004.
11. Gillet JP, Schneider J, Bertholet V, de Longueville F, Remacle J and Efferth T: Microarray expression profile of ABC transporters in Human Breast Cancer. Cancer Genomics Proteomics 3: 97-106, 2006.
12. Efferth T, Olbrich A and Bauer R: mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem Pharmacol 64: 617-623, 2002.
13. Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E and Davey R: Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukaemia cells. Blood Cells Mol Dis 28: 160-168, 2002.
14. Efferth T, Sauerbrey A, Halatsch ME, Ross DD and Gebhart E: Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines. Naunyn Schmiedebergs Arch Pharmacol 367: 56-67, 2003.
15. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD, Ross DD and Funk JO: Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 64: 382-394, 2003.
16. Efferth T and Kaina B: Microarray-based prediction of cytotoxicity of tumor cells to arsenic trioxide. Cancer Genomics Proteomics 1: 363-370, 2004.
17. Efferth T, Chen Z, Kaina B and Wang G: Molecular determinants of response to berberine. Cancer Genomics Proteomics 2: 115-124, 2005.
18. Borchers AT, Hackman RM, Keen CL, Stern JS and Gershwin ME: Complementary medicine: a review of immunomodulatory effects of Chinese herbal medicines. Am J Clin Nutr 66: 1303-1312, 1997.
19. Ikegami F, Fujii Y, Ishihara K and Satoh T: Toxicological aspects of Kampo medicines in clinical use. Chem Biol Interact 145: 235-250, 2003.
20. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH and Boyd MR: Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589-601, 1988.
21. Rubinstein LV, Shoemaker RH, Pauli KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A and Boyd MR: Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113-1118, 1990.
22. Wosikowski K, Schuurhuis D, Johnson K, Pauli KD, Myers TG, Weinstein JN and Bates SE: Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst 89: 1505-1515, 1997.
23. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO and Weinstein JN: A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244, 2000.
24. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WO, Weinstein JN, Mesirov JP, Lander ES and Golub TR: Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 98: 10787-10792, 2001.
25. Miller MG, Rodgers A and Cohen GM: Mechanisms of toxicity of naphthoquinones to isolated hepatocytes. Biochem Pharmacol 35: 1177-1184, 1986.
26. Moore HW: Bioactivation as a model for drug design bioreductive alkylation. Science 197: 527-532, 1977.
27. Ahn BZ, Baik KU, Kweon GR, Lim K and Hwang BD: Acylshikonin analogues: synthesis and inhibition of DNA topoisomerase-I. J Med Chem 38: 1044-1047, 1995.
28. Fujii N, Yamashita Y, Arima Y, Nagashima M and Nakano H: Induction of topoisomerase II-mediated DNA cleavage by the plant naphthoquinones plumbagin and shikonin. Antimicrob Agents Chemother 36: 2589-2594, 1992.
29. Lu Q, Liu W, Ding J, Cai J and Duan W: Shikonin derivatives: synthesis and inhibition of human telomerase. Bioorg Med Chem Lett 12: 1375-1378, 2002.
30. Papageorgiou VP, Assimopoulou AN, Couladouros EA, Hepworth D and Nicolaou KC: The chemistry and biology of alkannin, shikonin, and related naphthazarin natural products. Angew Chem Int Ed 38: 270-300, 1999.
31. Efferth T, Dunstan H, Sauerbrey A, Miyachi H and Chitambar CR: The anti-malarial artesunate is also active against cancer. Int J Oncol 18: 767-773, 2001.
32. Efferth T, Olbrich A, Sauerbrey A, Ross DD, Gebhart E and Neugebauer M: Activity of ascaridol from the anthelmintic herb Chenopodium anthelminticum L. against sensitive and multidrug-resistant tumor cells. Anticancer Res 22: 4221-4224, 2002.
33. Efferth T, Briehl MM and Tome ME: Role of antioxidant genes for the activity of artesunate against tumor cells. Int J Oncol 23: 1231-1235, 2003.
34. Efferth T and Oesch F: Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines. Biochem Pharmacol 68: 3-10, 2004.
35. Efferth T, Benakis A, Romero MR, Tomicic M, Rauh R, Steinbach D, Hafer R, Stamminger T, Oesch F, Kaina B and Marschall M: Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med 37: 998-1009, 2004.
36. Efferth T, Ramirez T, Gebhart E and Halatsch ME: Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem Pharmacol 67: 1689-1700, 2004.
37. Dell'Eva R, Pfeffer U, Vene R, Anfosso L, Forlani A, Albini A and Efferth T: Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol 68: 2359-2366, 2004.
38. Rinner B, Siegl V, Purstner P, Efferth T, Brem B, Greger H and Pfragner R: Activity of novel plant extracts against medullary thyroid carcinoma cells. Anticancer Res 24: 495-500, 2004.
39. Efferth T: Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist Updat 8: 85-97, 2005.
40. Efferth T: Microarray-based prediction of cytotoxicity of tumor cells to cantharidin. Oncol Rep 13: 459-463, 2005.
41. Efferth T and Volm M: Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate. In Vivo 19: 225-232, 2005.
42. Efferth T, Rauh R, Kahl S, Tomicic M, Boechzelt H, Tome ME, Briehl MM, Bauer R and Kaina B: Molecular modes of action of cantharidin in tumor cells. Biochem Pharmacol 69: 811-818, 2005.
43. Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A and Schuler G: Artesunate in the treatment of metastatic uveal melanoma - first experiences. Oncol Rep 14: 1599-1603, 2005.
44. Efferth T: Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr Drug Targets 7: 407-421, 2006.
45. Adams M, Efferth T and Bauer R: Activity-guided isolation of scopoletin and isoscopoletin, the inhibitory active principles towards CCRF-CEM leukaemia cells and multi-drug resistant CEM/ADR5000 cells, from Artemisia argyi. Planta Med 72: 862-864, 2006.
46. Anfosso L, Efferth T, Albini A and Pfeffer U: Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics J 6: 269-278, 2006.